Nitisinone

Nitisinone (also known as NTBC, an abbreviation of its full chemical name) is a drug used to slow the effects of hereditary tyrosinemia type 1. Since its first use for this indication in 1991, it has replaced liver transplantation as the first-line treatment for this rare condition. It is also being studied in the related condition alkaptonuria. It is marketed under the brand name Orfadin by the company, Swedish Orphan Biovitrum (Sobi) after having originally been brought to market by Swedish Orphan International. It was originally developed as candidate herbicide.